Utama › Limfoma › Missouri › St. Louis
Kajian klinikal Limfoma di St. Louis, MO
15 kajian untuk Limfoma sedang mencari peserta di lokasi dalam dan sekitar St. Louis (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Mengambil pesertaFasa 1
- Washington University School of Medicine - Oncology Hospital - Public, St Louis
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Mengambil pesertaFasa 2
- Washington University School of Medicine in St. Louis, St Louis
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Mengambil pesertaFasa 1/2
- Washington University School of Medicine in St. Louis, St Louis
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Mengambil pesertaFasa 1
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at West County Hospital, Creve Coeur · 12 mi jauh
Collection of Tissue Samples for Cancer Research
Mengambil pesertaKajian pemerhatian
- Washington University - St. Louis, St Louis
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Mengambil pesertaFasa 1/2
- Washington University School of Medicine, St Louis
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Mengambil pesertaFasa 1
- Washington University School of Medicine, St Louis
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Mengambil pesertaFasa 1
- Washington University School of Medicine/Siteman Cancer Center, St Louis
DALY II USA/ MB-CART2019.1 for DLBCL
Mengambil pesertaFasa 2
- Washington University, St. Louis, St Louis
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Mengambil peserta
- Washington University School of Medicine, St Louis
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Mengambil pesertaKajian pemerhatian
- Washington University School of Medicine, St Louis
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Mengambil pesertaFasa 3
- Saint Louis University, St Louis
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Mengambil pesertaFasa 2
- Washington University, St Louis
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
Mengambil pesertaFasa 3Sukarelawan sihat dialu-alukan
- OSF Saint Anthony's Health Center, Alton · 18 mi jauh
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Mengambil pesertaFasa 1/2
- Washington University, St Louis
Kajian Limfoma di bandar lain
- Houston, TX34 kajian
- Boston, MA33 kajian
- New York City, NY33 kajian
- Washington, DC23 kajian
- Baldwin Park, CA21 kajian
- Chicago, IL20 kajian
- Durham, NC17 kajian
- Philadelphia, PA15 kajian
- Cleveland, OH14 kajian
- Edison, NJ12 kajian
- Atlanta, GA12 kajian
- Seattle, WA12 kajian
Kajian lain di St. Louis
- Kanser Paru-paru Bukan Sel Kecil73 kajian
- Kanser Payudara64 kajian
- Kanser Metastatik54 kajian
- Kanser Kolorektal50 kajian
- Kanser Prostat46 kajian
- Kanser (semua jenis)46 kajian
- Kanser Paru-paru39 kajian
- Kanser Ovari38 kajian
- Kanser Pankreas33 kajian
- Kanser Endometrium29 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher28 kajian
- Kegagalan Jantung26 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.